Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ProSkelia SA, Strakan deal

Bone and skin diseases company Strakan will merge with musculoskeletal company ProSkelia to form a specialty pharma company with R&D capability and a European

Read the full 248 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE